GP-100 antigen: all 30 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaCompletedNCT00094653Phase 3Results posted
- Peptide Vaccination for Patients at High Risk for Recurrent MelanomaCompletedNCT00059475Phase 2Results posted
- Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic MelanomaCompletedNCT00019682Phase 3Results posted
- Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV MelanomaCompletedNCT00470015Phase 1
- Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic MelanomaCompletedNCT00091143Phase 1
- Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaStatus unknownNCT00085397Phase 2
- Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced MelanomaCompletedNCT00080353Phase 2
- Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV MelanomaCompletedNCT00077532Phase 2
- Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic MelanomaCompletedNCT00072085Phase 2
- Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00032045Phase 2
- Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With MelanomaCompletedNCT00031733Phase 2
- Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During SurgeryCompletedNCT00025181Phase 1
- Vaccine Therapy in Treating Patients With Metastatic Melanoma of the EyeCompletedNCT00020475Phase 2
- Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00019994Phase 2
- Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00019721Phase 2
- Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00019669Phase 2
- Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00019448Phase 2
- Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00019214Phase 1/2
- Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic MelanomaCompletedNCT00019175Phase 1
- Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV MelanomaStatus unknownNCT00010309Phase 1/2
- Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00006385Phase 2
- Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV MelanomaTerminatedNCT00006113Phase 2
- Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaTerminatedNCT00005841Phase 1
- Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant MelanomaCompletedNCT00003897Phase 1
- Vaccine Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00003665Phase 1
- Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00003568Phase 2
- Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00003339Phase 2
- Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by SurgeryCompletedNCT00003274Phase 2
- Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal SequenceCompletedNCT00001705Phase 2
- A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's AdjuvantCompletedNCT00001439Phase 1